Here is a comprehensive review of the 2017 hemophilia A therapeutic emicizumab [HEMLIBRA]. The author, Michael A. Nardi, MD, NYU Langone Health, details the effects of emicizumab on standard clot-based laboratory assays and the need for chromogenic substrate test methods. Click Nardi MA. Emicizumab and the clinical laboratory. Clin Lab Sci 2017; 30.DOI: https://doi.org/10.29074/ascls.119.002204.